Clinicopathologic features and treatment options of ocular adnexal lymphoma

References

• Fitzpatrick PJ, Macko S. Lymphoreticular tumors of the orbit. Int. J. Radiat. Oncol. Biol. Phys.10, 333–340 (1984).
   PubMed Web of Science ®Google Scholar
• Lambo MJ, Brady LW, Shields CL. Lymphoid tumors of the orbit. In: Radiotherapy of Intraocular and Orbital Tumors. Alberti WE, Sagerman RH (Eds). Springer-Verlag, Berlin, Germany, 205–216 (1993).
   Google Scholar
• Feinstein AR, Krause AC. Ocular involvement in lymphomatous disease. Am. Arch. Ophthalmol.48, 328–337 (1952).
   PubMed Web of Science ®Google Scholar
• Margo CE, Mulla ZD. Malignant tumors of the orbit. Analysis of the Florida Cancer Registry. Ophthalmology105, 185–190 (1998).
   PubMed Web of Science ®Google Scholar
• Sjö LD, Ralfkiaer E, Prause JU et al. Increasing incidence of ophthalmic lymphoma in Denmark from 1980 to 2005. Invest. Ophthalmol. Vis. Sci.49(8), 3283–3288 (2008).
   PubMed Web of Science ®Google Scholar
• Coupland S, Damato B. Understanding intraocular lymphomas. Clin. Exp. Ophthalmol.36, 564–578 (2008).
   PubMed Web of Science ®Google Scholar
• Cassoux N, Merle-Beral H, Leblond V et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul. Immunol. Inflamm.8, 243–250 (2000).
   PubMed Web of Science ®Google Scholar
• Buggage RR, Chan CC, Nussenblatt RB. Ocular manifestations of central nervous system lymphoma. Curr. Opin. Oncol.13, 137–142 (2001).
   PubMed Web of Science ®Google Scholar
• Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control11, 285–295 (2004).
   PubMedGoogle Scholar
• Ferreri AJ, Blay JY, Pasini F et al.; International Extranodal Study Group (IELSG). Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann. Oncol.13, 531–538 (2002).
   PubMed Web of Science ®Google Scholar
• Akpek EK, Ahmed I, Hochberg FH et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology106, 1805–1810 (1999).
   PubMed Web of Science ®Google Scholar
• Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes. Arch. Clin. Exp. Ophthalmol.242, 901–903 (2004).
   PubMed Web of Science ®Google Scholar
• Herrlinger U. Primary CNS lymphoma: findings outside the brain. J. Neurooncol.43(3), 227–230 (1999).
   PubMed Web of Science ®Google Scholar
• Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A et al. Ophthalmologic and intraocular non-Hodgkin’s lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Hematol. Oncol.22, 143–158 (2004).
   PubMed Web of Science ®Google Scholar
• Streubel B, Simonitsch-Klupp I, Müllauer L et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia18, 1722–1726 (2004).
   PubMed Web of Science ®Google Scholar
• Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL. Ocular adnexal lymphoma: a review of clinicopathological features and treatment options. Blood108(5), 1451–1460 (2006).
   PubMed Web of Science ®Google Scholar
• Rawal A, Finn WG, Schnitzer B et al. Site-specific morphologic differences in extranodal marginal zone B-cell lymphomas. Arch. Pathol. Lab. Med.131, 1673–1678 (2007).
   PubMedGoogle Scholar
• Lagoo AS, Haggerty C, Kim Y et al. Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classification: are marginal zone lymphomas in the orbit mucosa-associated lymphoid tissue-type lymphomas? Arch. Pathol. Lab. Med.132(9), 1405–1406 (2008).
   PubMed Web of Science ®Google Scholar
• Decaudin D, Dolcetti R, de Cremoux P et al. Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations? Anticancer Drugs19(8), 761–765 (2008).
   PubMedGoogle Scholar
• Plotkin SR, Batchelor TT. Advances in the therapy of primary central nervous system lymphoma. Clin. Lymphoma1, 263–275 (2001).
   PubMedGoogle Scholar
• Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, France (2008).
   Google Scholar
• Bessell EM, Henk JM, Wright JE, Whitelocke RA. Orbital and conjunctival lymphoma treatment and prognosis. Radiother. Oncol.13, 237–244 (1988).
   PubMed Web of Science ®Google Scholar
• White WL, Ferry JA, Harris NL, Grove AS Jr. Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology102, 1994–2006 (1995).
   PubMed Web of Science ®Google Scholar
• Esik O, Ikeda H, Mukai K, Kaneko A. A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin’s lymphomas. Radiother. Oncol.38, 13–18 (1996).
   PubMed Web of Science ®Google Scholar
• Restrepo A, Raez LE, Byrne GE Jr et al. Is central nervous system prophylaxis necessary in ocular adnexal lymphoma? Crit. Rev. Oncog.9, 269–273 (1998).
   PubMed Web of Science ®Google Scholar
• Johnson TE, Tse DT, Byrne GE Jr et al. Ocular-adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal. Plast. Reconstr. Surg.15, 171–179 (1999).
   PubMed Web of Science ®Google Scholar
• Nakata M, Matsumo Y, Katsumata N et al. Histology according to the Revised European–American Lymphoma classification significantly predicts the prognosis of ocular adnexal lymphoma. Leuk. Lymphoma32, 533–543 (1999).
   PubMed Web of Science ®Google Scholar
• Jenkins C, Rose GE, Bunce C et al. Histologic features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br. J. Ophthalmol.84, 907–913 (2000).
   PubMed Web of Science ®Google Scholar
• Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Graff A, Buchen R, Witschel H. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Br. J. Ophthalmol.85, 63–69 (2001).
   PubMed Web of Science ®Google Scholar
• Sasai K, Yamabe H, Dodo Y, Kashii S, Nagata Y, Hiraoka M. Non-Hodgkin’s lymphoma of the ocular adnexa. Acta Oncol.40, 485–490 (2001).
   PubMed Web of Science ®Google Scholar
• Stafford SL, Kozelsky TF, Garrity JA et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother. Oncol.59, 139–144 (2001).
   PubMed Web of Science ®Google Scholar
• Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC. Curative radiotherapy for primary orbital lymphoma. Int. J. Radiat. Oncol. Biol. Phys.54, 818–823 (2002).
   PubMed Web of Science ®Google Scholar
• Cho EY, Han JJ, Ree HJ et al. Clinicopathologic analysis of ocular adnexal lymphoma: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am. J. Hematol.73, 87–96 (2003).
   PubMed Web of Science ®Google Scholar
• Fung CY, Tarbell NJ, Lucarelli MJ et al. Ocular adnexal lymphoma: clinical behavior of distinct WHO classification subtypes. Int. J. Radiat. Oncol. Biol. Phys.57, 1382–1391 (2003).
   PubMed Web of Science ®Google Scholar
• Martinet S, Ozsahin M, Belkacemi Y et al. Outcome and prognostic factors in orbital lymphoma: a rare cancer network study on 90 consecutive patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.55, 892–898 (2003).
   PubMed Web of Science ®Google Scholar
• Uno T, Isobe K, Shikama N et al. Radiotherapy for extranodal, marginal-zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa. Cancer98, 865–871 (2003).
   PubMed Web of Science ®Google Scholar
• Adachi A, Tamaru J-I, Kaneko K et al. No evidence of a correlation between BCL10 expression API2–MALT1 gene rearrangement in ocular adnexal MALT lymphoma. Pathol. Intern.54, 16–25 (2004).
   PubMed Web of Science ®Google Scholar
• Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes. Arch. Clin. Exp. Ophthalmol.242, 130–145 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JL, Kim MK, Lee KH et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann. Hematol.84, 13–18 (2005).
   PubMed Web of Science ®Google Scholar
• Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch. Ophthalmol.125(12), 1663–1667 (2007).
   PubMed Web of Science ®Google Scholar
• Plaisier MB, Sie-Go DM, Berendschot TT, Petersen EJ, Mourits MP. Ocular adnexal lymphoma classified using the WHO classification: not only histology and stage, but also gender is a predictor of outcome. Orbit26(2), 83–88 (2007).
   PubMedGoogle Scholar
• Tanimoto K, Kaneko A, Suzuki S et al. Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Jpn. J. Clin. Oncol.37(5), 337–344 (2007).
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Vassilakopoulos TP et al. Non-gastric extra-nodal marginal zone lymphomas – a single centre experience on 76 patients. Leuk. Lymphoma49(12), 2308–2315 (2008).
   PubMed Web of Science ®Google Scholar
• Logoo AS, Haggerty C, Kim Y et al. Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization Classification. Arch. Pathol. Lab. Med.132, 1405–1416 (2008).
   PubMedGoogle Scholar
• Sjö LD, Heegarrd S, Prause JU, Petersen BL, Pedersen S, Ralfkiaer E. Extranodal marginal zone lymphoma in the ocular region: clinical, immunophenotypical, and cytogenetical characteristics. Invest. Ophthalmol. Vis. Sci.50(2), 516–522 (2009).
   PubMed Web of Science ®Google Scholar
• Sjö LD. Ophtalmic lymphoma: epidemiology and pathogenesis. Acta. Ophtalmol.87(Thesis 1), 1–20 (2009).
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle cell lymphoma. Ann. Oncol.6, 257–262 (1995).
   PubMed Web of Science ®Google Scholar
• Harris N, Jaffe ES, Stein H et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study group. Blood84, 1361–1392 (1994).
   PubMed Web of Science ®Google Scholar
• Rasmussen P, Sjö LD, Prause JU, Ralfkiaer E, Heegaard S. Mantle cell lymphoma in the orbital and adnexal region. Br. J. Ophthalmol.93, 1047–1051 (2009).
   PubMed Web of Science ®Google Scholar
• Madge SN, McCormick A, Patel I et al. Ocular adnexal diffuse large B-cell lymphoma: local disease correlates with better outcomes. Eye (2009) (Epub ahead of print).
   Google Scholar
• Precupanu CM, Validire P, Lévy C et al. Primary high-grade ocular adnexal lymphoma: clinico-pathological characteristics and prognostic factors of a single centre series. Am. J. Hematol. (2010) (In press).
   PubMedGoogle Scholar
• Sharara N, Holden JT, Wojno TH, Feinberg AS, Grossniklaus HE. Ocular adnexa lymphoid proliferations: clinical, histologic, flow cytometric, and molecular analysis of forty-three cases. Ophthalmology110, 1245–1254 (2003).
   PubMed Web of Science ®Google Scholar
• Chen PM, Chiou TJ, Yu IT et al. Molecular analysis of mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexa. Leuk. Lymphoma42, 207–214 (2001).
   PubMed Web of Science ®Google Scholar
• Chen PM, Liu JH, Yu IT et al. Lack of mutations of BCL6 and BCL10 genes in mucosa-associated lymphoid tissue lymphomas of the orbital adnexa. Cancer Genet. Cytogenet.123, 44–48 (2000).
   PubMedGoogle Scholar
• Zhu J, Wei RL, Wang LH, Jiao BH. Significance of detection of Bcl-10 novel mutation in ocular adnexal mucosa-associated lymphoid tissue lymphoma. Zhonghua. Yan. Ke. Za. Zhi.43(11), 1010–1016 (2007).
   PubMedGoogle Scholar
• Li BZ, Zhou XY, Ye HT et al. Abnormal expression of Bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type. Zhonghua. Bing. Li. Xue. Za. Zhi.36(12), 819–824 (2007).
   PubMedGoogle Scholar
• Li BZ, Lu HF, Zhou XY et al. Frequency of genetic aberrations in mucosa-associated lymphoid tissue lymphoma of different sites. Zhonghua. Bing. Li. Xue. Za. Zhi.37(9), 604–608 (2008).
   PubMedGoogle Scholar
• Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia19, 652–658 (2005).
   PubMed Web of Science ®Google Scholar
• Ness GO, Lyboek H, Arnes J, Rodahl E. Chromosomal imbalances in lymphoid tumors of the orbit. Invest. Ophthalmol. Vis. Sci.43, 9–14 (2002).
   PubMedGoogle Scholar
• Matteucci C, Galieni P, Leoncini L et al. Typical genomic imbalances in primary MALT lymphoma of the orbit. J. Pathol.200, 656–660 (2003).
   PubMed Web of Science ®Google Scholar
• Kim WS, Honma K, Karnan S et al. Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma. Genes Chromosomes Cancer46(8), 776–783 (2007).
   PubMed Web of Science ®Google Scholar
• Levine EG, Arthur DC, Machnicki J et al. Four new recurring translocations in non-Hodgkin’s lymphoma. Blood74, 1796–1800 (1989).
   PubMed Web of Science ®Google Scholar
• Horsman D, Gascoyne R, Klasa R, Coupland R. t(11;18)(q21;q21.1): a recurring translocation in lymphomas in mucosa-associated lymphoid tissue (MALT)? Genes Chromosome Cancer4, 183–187 (1992).
   PubMed Web of Science ®Google Scholar
• Akagi T, Motegi M, Tamura A et al. A novel gene, MALT1 at 18q21, is involved in t(11;18)(q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene18, 5785–5794 (1999).
   PubMed Web of Science ®Google Scholar
• Dierlamm J, Baens M, Wlodarska I et al. The apoptosis inhibitor gene AP12 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood93, 3601–3609 (1999).
   PubMed Web of Science ®Google Scholar
• Morgan JA, Yin Y, Borowsky AD et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res.59, 6205–6213 (1999).
   PubMed Web of Science ®Google Scholar
• Wotherspoon AC, Pan LX, Diss TC, Isaacson PG. Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet. Cytogenet.58, 35–38 (1992).
   PubMed Web of Science ®Google Scholar
• Willis TG, Jadayel DM, Du MQ et al.Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell96, 35–45 (1999).
   PubMed Web of Science ®Google Scholar
• Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat. Rev. Immunol.4, 348–359 (2004).
   PubMed Web of Science ®Google Scholar
• Lucas PC, Yonezumi M, Inohara N et al.Bcl10 and MALT1, independent targets of chromosomal translocation in MALT lymphoma, cooperate in a novel NF-κB signalling pathway. J. Biol. Chem.276, 19012–19019 (2001).
   PubMed Web of Science ®Google Scholar
• Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol.16, 225–226 (1998).
   PubMed Web of Science ®Google Scholar
• Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol.18, 621–623 (2000).
   PubMed Web of Science ®Google Scholar
• Novak U, Rinaldi A, Kwee I et al. The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood113(20), 4918–1921 (2009).
   PubMed Web of Science ®Google Scholar
• Chanudet E, Ye H, Ferry J et al.A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J. Pathol.217, 420–430 (2009).
   PubMed Web of Science ®Google Scholar
• Honma K, Tsuzuki S, Nakagawa M et al.TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood114(12), 2467–2475 (2009).
   PubMed Web of Science ®Google Scholar
• Gascoyne RD. The molecular biology of MALT lymphoma. Hematology Am. Soc. Hematol. Educ. Program244–248 (2001).
   Google Scholar
• Morgner A, Sutton P, O’Rourke JL, Enno A, Dixon MF, Lee A. Helicobacter-induced expression of Bcl-X(L) in B lymphocytes in the mouse model: a possible step in the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Int. J. Cancer92, 634–640 (2001).
   PubMedGoogle Scholar
• Seeberger H, Starostik P, Schwarz S et al. Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. Lab. Invest.81, 977–986 (2001).
   PubMedGoogle Scholar
• D’Elios MM, Amedei A, Manghetti M et al. Impaired T-cell regulation of B-cell growth in Helicabacter pylori-related gastric low-grade MALT lymphoma. Gastroenterology117, 1105–1112 (1999).
   PubMed Web of Science ®Google Scholar
• Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet338, 1175–1176 (1991).
   PubMed Web of Science ®Google Scholar
• Shen DF, Herbort CP, Tuaillon N, Buggage RR, Egwuagu CE, Chan CC. Detection of Toxoplasma gondii DNA in primary intraocular B-cell lymphoma. Mod. Pathol.14, 995–999 (2001).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Guidoboni M, Ponzoni M et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphoma. J. Natl Cancer Inst.96, 586–594 (2004).
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Ferreri AJ, Guidoboni M et al.Chlamydia infection and lymphomas : association beyond ocular adnexal lymphomas highlighted by multiple detection methods. Clin. Cancer Res.14(18), 5794–5800 (2008).
   PubMed Web of Science ®Google Scholar
• Aigelsreiter A, Leitner E, Deutsch AJ et al.Chlamydia psittaci in MALT lymphomas of ocular adnexals: the Austrian experience. Leuk. Res.32(8), 1292–1294 (2008).
   PubMedGoogle Scholar
• Matthews JM, Moreno LI, Dennis J et al. Ocular adnexal lymphoma: no evidence for bacterial DNA associated with lymphoma pathogenesis. Br. J. Haematol.142(2), 246–249 (2008).
   PubMedGoogle Scholar
• Bahler DW, Szankasi P, Kulkarni S, Tubbs RR, Cook JR, Swerdlow SH. Use of similar immunoglobulin VH gene segments by MALT lymphomas of the ocular adnexa. Mod. Pathol.22(6), 833–838 (2009).
   PubMed Web of Science ®Google Scholar
• Nutting CM, Shah-Desai S, Rose GE, Norton AP, Plowman PN. Thyroid orbitopathy possibly predisposes to late-onset of periocular lymphoma. Eye20(6), 645–648 (2005).
   PubMedGoogle Scholar
• Chazerain P, Meyer O, Kaplan G et al. Lymphomas of the ocular adnexa in Gougerot–Sjogren syndrome. Apropos of 4 cases. Ann. Med. Interne (Paris)146, 223–225 (1995).
   PubMedGoogle Scholar
• Tonami H, Matoba M, Yokota H, Higashi K, Yamamoto I, Sugai S. Mucosa-associated lymphoid tissue lymphoma in Sjogren’s syndrome: initial and follow-up imaging features. Am. J. Roentgenol.179, 485–189 (2002).
   PubMed Web of Science ®Google Scholar
• Dhermy P, Diebold J, Audoin J, Tricot G. Pseudo-lymphomas of the ocular adnexa: their relations to Sjogren’s syndrome (author’s transl). J. Fr. Ophtalmol.4, 787–796 (1981).
   PubMedGoogle Scholar
• Takeshita S, Sugai S, Ogawa Y et al. A case of Sjogren’s syndrome with an eyelid tumor, a so-termed pseudolymphoma of the lacrimal gland. Ryumachi36, 43–49 (1996).
   PubMedGoogle Scholar
• Yago T, Nishinarita M. A case of Sjogren’s syndrome with marked lacrimal gland enlargement, atypical onset and IgA–M-proteinemia. Nihon Rinsho Meneki Gakkai Kaishi25, 466–472 (2002).
   PubMedGoogle Scholar
• Cheuk W, Yuen HK, Chan AC et al. Ocular adnexal lymphoma associated with IgG4+ chronic sclerosing dacryoadenitis: a previously undescribed complication of IgG4-related sclerosing disease. Am. J. Surg. Pathol.32(8), 1159–1167 (2008).
   PubMed Web of Science ®Google Scholar
• Jenkins C, Rose GE, Bunce C et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye17, 809–820 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan TJ, Whitehead K, Williamson R et al. Lymphoproliferative disease of the ocular adnexa: a clinical and pathologic study with statistical analysis of 69 patients. Ophthal. Plast. Reconstr. Surg.21, 177–188 (2005).
   PubMed Web of Science ®Google Scholar
• Charlotte F, Doghmi K, Cassoux N et al. Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. Virchows Arch.448(4), 506–516 (2006).
   PubMed Web of Science ®Google Scholar
• Rosado MF, Byrne GE Jr, Ding F et al. Ocular adnexal lymphoma: a clinicopathological study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood107, 467–472 (2006).
   PubMed Web of Science ®Google Scholar
• Glass AG, Karnell LH, Menck HR. Data base report on non-Hodgkin’s lymphoma. Cancer80, 2311–2320 (1997).
   PubMed Web of Science ®Google Scholar
• Thiéblemont C, Berger F, Dumontet C. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood95, 802–806 (2000).
   PubMed Web of Science ®Google Scholar
• Tsang RW, Gospodarowicz MK, Pintilie M et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J. Clin. Oncol.21, 4157–4164 (2003).
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Pedrinis E. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood101, 2489–2495 (2003).
   PubMed Web of Science ®Google Scholar
• Meunier C, Lumbroso-Le Rouïc L, Dendale R et al. Conjunctival low-grade non-Hodgkin’s lymphoma: a large single-center study of initial characteristics, natural history, and prognostic factors. Leuk. Lymphoma47(7), 1295–305 (2006).
   PubMed Web of Science ®Google Scholar
• No authors listed. A predictive model for aggressive non-Hodgkin’s lymphoma: the International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N. Engl. J. Med.329, 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol.25, 579–586 (2007).
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol.5, 649–655 (1982).
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin’s disease staging classification. Cancer Res.31, 1860–1861 (1971).
   PubMed Web of Science ®Google Scholar
• Coupland SE, White VA, Rootman J, Damato B, Finger PT. A TNM-based staging system of ocular adnexal lymphomas. Arch. Pathol. Lab. Med.133(8), 1262–1267 (2009).
   PubMed Web of Science ®Google Scholar
• Bolek TW, Moyses HM, Marcus RB Jr et al. Radiotherapy in the management of orbital lymphoma. Int. J. Radiat. Oncol. Biol. Phys.44, 31–36 (1999).
   PubMed Web of Science ®Google Scholar
• Vitu L, Cosset JM, Briot E et al. Malignant non-Hodgkin’s lymphoma of the conjunctiva. A propos of 14 cases treated at the Institut Gustave-Roussy. Bull. Cancer Radiother.77, 61–68 (1990).
   PubMedGoogle Scholar
• Letschert JG, Gonzalez Gonzalez D, Oskam J et al. Results of radiotherapy in patients with stage I orbital non-Hodgkin’s lymphoma. Radiother. Oncol.22, 36–44 (1991).
   PubMed Web of Science ®Google Scholar
• Smitt MC, Donaldson SS. Radiotherapy is successful treatment for orbital lymphoma. Int. J. Radiat. Oncol. Biol. Phys.26, 59–66 (1993).
   PubMed Web of Science ®Google Scholar
• Chao CK, Lin HS, Devineni VR, Smith M. Radiation therapy for primary orbital lymphoma. Int. J. Radiat. Oncol. Biol. Phys.31, 929–934 (1995).
   PubMed Web of Science ®Google Scholar
• Erkal HS, Serin M, Sak SD, Cakmak A. Radiation therapy for stage I primary orbital non-Hodgkin’s lymphomas. Tumori83, 822–825 (1997).
   PubMed Web of Science ®Google Scholar
• Lau HY, Chua ET, Yang TL, Chua EJ. Orbital lymphoma: results of radiation therapy. Ann. Acad. Med. Singapore.27, 474–477 (1998).
   PubMedGoogle Scholar
• Le QT, Eulau SM, George TI et al. Primary radiotherapy for localized orbital MALT lymphoma. Int. J. Radiat. Oncol. Biol. Phys.52, 657–663 (2002).
   PubMed Web of Science ®Google Scholar
• Liao SL, Kao SC, Hou PK, Chen MS. Results of radiotherapy for orbital and adnexal lymphoma. Orbit21, 117–123 (2002).
   PubMedGoogle Scholar
• Hasegawa M, Kojima M, Shioya M et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int. J. Radiat. Oncol. Biol. Phys.57, 172–176 (2003).
   PubMed Web of Science ®Google Scholar
• Ejima Y, Sasaki R, Okamoto Y et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother. Oncol.78(1), 6–9 (2005).
   PubMedGoogle Scholar
• Suh C, Huh J, Roh JL. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the extracranial head and neck region: a high rate of dissemination and disease recurrence. Oral Oncol.44(10), 949–955 (2008).
   PubMed Web of Science ®Google Scholar
• Baldini L, Blini M, Guffanti A et al. Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Ann. Oncol.9, 779–781 (1998).
   PubMed Web of Science ®Google Scholar
• Rigacci L, Nassi L, Puccioni M et al. Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas. Ann. Hematol.86, 565–568 (2007).
   PubMed Web of Science ®Google Scholar
• Song E-K, Kim S-Y, Kim TM et al. Efficacy of chemotherapy as a front-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann. Oncol.19, 242–246 (2008).
   PubMed Web of Science ®Google Scholar
• Troch M, Jonak C, Müllauer L et al. A Phase II of bortezomib in patients with MALT lymphomas. Haematologica94(5), 738–742 (2009).
   PubMed Web of Science ®Google Scholar
• Blasi MA, Gherlinzoni F, Calvisi G et al. Local chemotherapy with interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report. Ophthalmology108, 559–562 (2001).
   PubMed Web of Science ®Google Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-type progression of B lymphocytes. Immunol. Today.15, 450–454 (1994).
   PubMedGoogle Scholar
• Reff ME, Carner K, Chambers KS et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood83, 435–445 (1994).
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press O. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood91, 1644–1652 (1998).
   PubMed Web of Science ®Google Scholar
• Mathas S, Rickers A, Bommert, K, Dörken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res.60, 7170–7176 (2000).
   PubMed Web of Science ®Google Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-c2b8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm.12, 177–186 (1997).
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity either drug alone. Br. J. Haematol.114, 800–809 (2001).
   PubMed Web of Science ®Google Scholar
• Sacchi S, Federico M, Vitolo U et al. Clinical activity and safety of combination immunotherapy with IFN-α2a and rituximab in patients with relapsed low grade non-Hodgkin’s lymphoma. Haematologica86, 951–958 (2001).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol.22, 4711–4716 (2004).
   PubMed Web of Science ®Google Scholar
• Salles G, Foussard C, Mounier N et al. Rituximab added to αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood104 (2004) (Abstract 160).
   PubMedGoogle Scholar
• Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood106, 3725–3732 (2005).
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood105, 1417–1423 (2005).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346, 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller E, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Blood24, 3121–3127 (2006).
   Google Scholar
• Pfreundschuh M, Truemper L, Gill D et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol.7, 357–359 (2006).
   PubMedGoogle Scholar
• Conconi A, Martinelli G, Thiéblemont C et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT-type. Blood102, 2741–2745 (2003).
   PubMed Web of Science ®Google Scholar
• Raderer M, Jager G, Brugger S et al. Rituximab for treatment of advanced extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology65, 306–310 (2003).
   PubMed Web of Science ®Google Scholar
• Datta YH, Kampalath B, Binion DG. Rituximab-induced remission of a gastric MALT lymphoma. Leuk. Lymphoma45, 1297–1299 (2004).
   PubMed Web of Science ®Google Scholar
• Nuckel H, Meller D, Steuhl KP, Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur. J. Haematol.73, 258–262 (2004).
   PubMed Web of Science ®Google Scholar
• Benabid L, Desablens B, Defossez T, Malthieu D, Milazzo S, Turut P. New treatment for orbital non-Hodgkin’s lymphoma: 2 cases treated with rituximab. J. Fr. Ophthalmol.28, 769–771 (2005).
   PubMedGoogle Scholar
• Chong EA, Svoboda J, Cherian S et al. Regression of pulmonary MALT lymphoma after treatment with rituximab. Leuk. Lymphoma46, 1383–1386 (2005).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Ponzoni M, Martinelli G et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica90, 1578–1579 (2005).
   PubMed Web of Science ®Google Scholar
• Martinelli G, Laszlo D, Ferreri AJ et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J. Clin. Oncol.23, 1979–1983 (2005).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Alinari L, Stefoni V, Loffredo A, Pichierri P, Polito E. Rituximab in primary conjunctiva lymphoma. Leuk. Res.29, 107–108 (2005).
   PubMed Web of Science ®Google Scholar
• Benetatos L, Alymara V, Asproudis I, Bourantas KL. Rituximab as first line treatment for MALT lymphoma of extraocular muscles. Ann. Hematol.85, 625–626 (2006).
   PubMedGoogle Scholar
• Chaudhary N, Ozer H, Huard D, Lightfoot S, Mesiya S. Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab. Dig. Dis. Sci.51, 775–778 (2006).
   PubMedGoogle Scholar
• Sokol JA, Landau L, Lauer SA. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up. Ophthal. Plast. Reconstr. Surg.25(4), 322–324 (2009).
   PubMedGoogle Scholar
• Erwin WD, Esmaeli B. Estimation of yttrium-90 Zevalin tumor-absorbed dose in ocular adnexal lymphoma using quantitative indium-111 Zevalin radionuclide imaging. Nucl. Med. Commun.30(9), 681–686 (2009).
   PubMedGoogle Scholar
• Esmaeli B, McLaughlin P, Pro B et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann. Oncol.20(4), 709–714 (2009).
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yoshino T. Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma. Ophthalmology111, 1233–1237 (2004).
   PubMed Web of Science ®Google Scholar
• Tanimoto K, Kaneko A, Suzuki S et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann. Oncol.17, 135–140 (2006).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Ponzoni M, Guidoboni M et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J. Clin. Oncol.23, 5067–5073 (2005).
   PubMed Web of Science ®Google Scholar
• Yeung L, Tsao YP, Chen PY, Kuo TT, Lin KK, Lai LJ. Combination of adult inclusion conjunctivitis and mucosa-associated lymphoid tissue (MALT) lymphoma in a young adult. Cornea231, 71–75 (2004).
   Google Scholar
• Coleman M, Leonard JP, Decter J et al. 2004. Periocular MALT (conjunctival/orbital) lymphomas: complete responses with antibiotic therapy. Blood104 (2004) (Abstract 2493).
   Google Scholar
• Grünberger B, Hauff W, Lukas J et al. ‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann. Oncol.17, 484–487 (2006).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Ponzoni M, Guidoboni M et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J. Natl Cancer Inst.98, 1375–1382 (2006).
   PubMed Web of Science ®Google Scholar
• Chanudet E, Zhou Y, Bacon CM et al.Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J. Pathol.209, 344–351 (2006).
   PubMed Web of Science ®Google Scholar
• Daibata M, Nemoto Y, Togitani K et al. Absence of Chlamydia psittaci in ocular adnexal lymphoma from Japanese patients. Br. J. Haematol.132, 651–661 (2006).
   PubMed Web of Science ®Google Scholar
• De Cremoux P, Subtil A, Ferreri AJM et al. Re: evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J. Natl Cancer Inst.98, 365–366 (2006).
   PubMed Web of Science ®Google Scholar
• Liu YC, Ohyashiki JH, Ito Y et al.Chlamydia psittaci in ocular adnexal lymphoma: Japanese experience. Leuk. Res.30, 1587–1589 (2006).
   PubMed Web of Science ®Google Scholar
• Mulder MM, Heddema ER, Pannekoek Y et al. No evidence for an association of ocular adnexal lymphoma with Chlamydia psittaci in a cohort of patients from the Netherlands. Leuk. Res.30, 1305–1307 (2006).
   PubMed Web of Science ®Google Scholar
• Vargas RL, Fallone E, Felgar RE et al. Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience. Leuk. Res.30, 547–551 (2006).
   PubMed Web of Science ®Google Scholar
• Goebel N, Serr A, Mittelviefhaus H, Reinhard T, Bogdan C, Auw-Haedrich C. Chlamydia psittaci, Helicobacter pylori and ocular adnexal lymphoma – is there an association? The German experience. Leuk. Res.31, 1450–1452 (2007).
   PubMed Web of Science ®Google Scholar
• Gracia E, Frösch P, Mazzucchelli L et al. Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. Leuk. Lymphoma48, 104–108 (2007).
   PubMed Web of Science ®Google Scholar
• Ruiz A, Reischl U, Swerdlow SH et al. Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. Am. J. Surg. Pathol.31, 792–802 (2007).
   PubMed Web of Science ®Google Scholar
• Yakushijin Y, Kodama T, Takaoka et al. Absence of chlamydial infection in Japanese patients with ocular adnexal lymphoma of mucosa-associated lymphoid tissue. Int. J. Hematol.85, 223–230 (2007).
   PubMed Web of Science ®Google Scholar
• Yoo C, Ryu M-H, Huh J et al.Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea. Am. J. Hematol.82, 821–823 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang GS, Winter JN, Variakojis D et al. Lack of an association between Chlamydia psittaci and ocular adnexal lymphoma. Leuk. Lymphoma48, 577–283 (2007).
   PubMed Web of Science ®Google Scholar
• Mollejo M, Camacho FI, Algara P, Ruiz-Ballesteros E, García JF, Piris MA. Nodal and splenic marginal zone B cell lymphomas. Hematol. Oncol.23, 108–118 (2005).
   PubMed Web of Science ®Google Scholar
• Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev.19, 39–51 (2005).
   PubMed Web of Science ®Google Scholar
• Oh SY, Ryoo B-Y, Kim WS et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am. J. Hematol.82, 446–452 (2007).
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Coiffier B. Management of marginal zone lymphomas. Curr. Treat. Options Oncol.7, 213–222 (2006).
   PubMedGoogle Scholar
• Arcaini L, Lazzarino M, Colombo N et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood107, 4643–4649 (2006).
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood104, 1258–1265 (2004).
   PubMed Web of Science ®Google Scholar